Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + ramucirumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Pembrolizumab + ramucirumab is a combination of two monoclonal antibody therapies used in oncology clinical trials. Pembrolizumab is a humanized IgG4-kappa monoclonal antibody that targets programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1 and PD-L2, thereby enhancing T-cell mediated immune responses against tumors. Ramucirumab is a fully human IgG1 monoclonal antibody that binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting the binding of VEGF ligands and thus blocking angiogenesis, which tumors require for growth and metastasis. The combination aims to synergistically enhance antitumor activity by both promoting immune-mediated tumor destruction (via checkpoint inhibition) and disrupting tumor blood supply (via antiangiogenic effects). This regimen has been studied in advanced cancers such as non-small cell lung cancer, head and neck squamous cell carcinoma, gastric/gastroesophageal junction adenocarcinoma, urothelial carcinoma, and biliary tract cancer[2][3][4][5].
- Other names
- pembrolizumab plus ramucirumabpembrolizumab and ramucirumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on pembrolizumab + ramucirumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + ramucirumab.